A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis
| Autor: | Wyngaert, F. A., Beguin, C., Marie D'hooghe, Dooms, G., Lissoir, F., Carton, H., Sindic, C. J. M. |
|---|---|
| Přispěvatelé: | Clinical sciences, Neuroprotection & Neuromodulation, Neurology |
| Jazyk: | angličtina |
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Methylprednisolone/adverse effects Patient Dropouts Alopecia/chemically induced Immunosuppressive Agents/adverse effects Phlebitis/chemically induced Vomiting/chemically induced contrast media Methylene Blue/therapeutic use Severity of Illness Index Nausea/chemically induced Pyrrolidines/therapeutic use Treatment Outcome Double-Blind Method Recurrence Mitoxantrone/adverse effects Humans magnetic resonance imaging Multiple Sclerosis/drug therapy Female Lymphocyte Count Pulmonary Embolism/etiology gadolinium Follow-Up Studies |
| Zdroj: | Vrije Universiteit Brussel Scopus-Elsevier |
| Popis: | A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis. Patients were randomized to receive 13 infusions of mitoxantrone 12 mg/m2 (n = 28), or 13 infusions of 1 g of methylprednisolone (n = 21), over 32 months. Twenty-four patients completed the trial. There were no statistical differences between the two groups of patients at study entry. A significant improvement in the Expanded Disability Scale Score (EDSS) was observed in the mitoxantrone group after one year of treatment (p < 0.0022). The total number of relapses, the mean number of relapses/patient/year, and the total number of gadolinium-enhanced lesions on bi-annual MRI scans were significantly decreased in the mitoxantrone group throughout the study period. Nausea, vomiting, and alopecia were more frequent in the mitoxantrone-treated patients. Mitoxantrone has a role in the treatment of MS patients with frequent exacerbations and rapid disease progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|